📇 Rhumatologue · PESSAC CEDEX · (33) · Hospitalier

M DAVID LAHARIE

Pourquoi vous devez consulter ce praticien

5 raisons identifiées

Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
43 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Expérience confirmée
20 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
144.4 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PESSAC CEDEX (33)HospitalierRPPS 10002814589

Expérience confirmée

20ans d'exercice (thèse 2006)

📊 Reconnaissance scientifique : 70/100📝 586 articles publiés🇫🇷 Publications académiques françaises (8)🎓 1 thèse dirigée

✨ Génération du profil synthétique IA en cours…

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

The lancet. Gastroenterology & hepatology · 2025

📚 26 citations🎯 RCR 10.60🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024

📚 22 citations🎯 RCR 4.27Top 10% NIH

Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial

Gut · 2025

📚 17 citations🎯 RCR 7.21🩺 Clinique

Lire l'abstract Crossref ↓

Background It is unknown which maintenance therapy is the most effective option for patients admitted for an acute severe ulcerative colitis (ASUC) episode responding to intravenous steroids. Methods We conducted a multicentre, parallel-group, open-label randomised controlled trial among 23 French centres in thiopurine and biologics-naïve adults admitted for ASUC responding to intravenous steroids. Eligible patients were randomly assigned to receive infliximab (IFX) and azathioprine (AZA) with a 7-day steroid tapering scheme (IFX+AZA arm) or AZA and conventional standardised steroid tapering regimen (AZA arm). The primary composite endpoint was treatment failure at week 52, defined as the absence of steroid-free clinical remission, the absence of endoscopic response, the use of a prohibited treatment for relapse, severe adverse event leading to treatment interruption, colectomy or death. Multiple imputation for missing data was performed. Findings Among the 64 patients randomised (Lichtiger score 13.5±2.0; median age of 34.5 (P25–P75 26.3–50.3) years, median C reactive protein of 29.0 (12.8–96.8) mg/L at baseline): 32 were assigned to the IFX+AZA arm and 32 to the AZA arm. In the ITT population, treatment failure at week 52 was observed in 22/27 (81.5%) in the AZA arm and 16/30 (53.3%) in the IFX+AZA arm (risk ratio 3.85, 95% CI (1.15 to 12.88), p=0.03). 29 adverse events were severe, including 13 disease exacerbations, 6 severe infections without any difference between both arms. Interpretation Combination therapy with IFX+AZA was more effective at 1 year than AZA alone to avoid treatment failure in patients with ASUC responding to intravenous steroids. Trial registration number NCT02425852 .

Cookies & analyse de trafic

M DAVID LAHARIE

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (43) — classées par pathologie

Transversal14

Anti-TNF9

JAK inhibiteurs8

Épidémiologie & registres3

Pharmacovigilance3

Anti-IL-232

Essai clinique2

Revue générale2

Vraie vie / RWE2

Activité physique / Rééducation1

Recommandations1

Revue / méta-analyse1

Datasets & protocoles partagés

Partager cette fiche